menu search

ACHL / Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)
Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript) Read More
Posted: Nov 12 2021, 20:36
Author Name: Seeking Alpha
Views: 102244

ACHL News  

Achilles Therapeutics to Present at Upcoming Conferences

By GlobeNewsWire
June 12, 2023

Achilles Therapeutics to Present at Upcoming Conferences

LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered p more_horizontal

Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

By Zacks Investment Research
February 2, 2023

Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year. more_horizontal

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By GlobeNewsWire
December 20, 2022

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered p more_horizontal

Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket

By Seeking Alpha
December 18, 2022

Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket

ACHL has about $4.40 of cash per share on hand, yet it trades below $1. I believe that recent selling is due to tax loss sellers needing to recognize more_horizontal

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

By GlobeNewsWire
November 30, 2022

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT mo more_horizontal

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

By GlobeNewsWire
April 4, 2022

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - more_horizontal

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

By Seeking Alpha
November 12, 2021

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript) more_horizontal

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

By Seeking Alpha
November 12, 2021

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript) more_horizontal


Search within

Pages Search Results: